Predictive Oncology appoints Matthew J. Hawryluk, Ph.D. to Board of Directors

Axe Compute Inc.

Appointed as Class II director effective Nov 29, 2022; fills vacancy from J. Melville Engle's retirement.
Currently EVP and Chief Business Officer at Gritstone bio (NASDAQ: GRTS).
Awarded $5,000 in common stock from the Company's 2012 Stock Incentive Plan.
Bringing experience from Foundation Medicine and Thermo Fisher Scientific; Ph.D. in cell biology and MBA.
His term expires at the 2023 annual meeting of stockholders.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew J. Hawryluk, Ph.D.

Class II director

AGPU · Axe Compute Inc.

Effective: 2022-11-29
Filed: December 5, 2022, 6:59 PM ET

Effective November 29, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected Matthew J. Hawryluk, Ph.D., to the Board as a Class II director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew J. Hawryluk, Ph.D. was elected as Class II director at Axe Compute Inc..

Action: elected
Role: Class II director

Exact text from the filing

Effective November 29, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected Matthew J. Hawryluk, Ph.D., to the Board as a Class II director.

View on SEC.gov

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.